The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2023 | KontRASt-01: JDQ443 and TNO155 in the treatment of NSCLC
Marcelo Negrao, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of the Phase Ib KontRASt-01 trial (NCT04699188) in which patients with non-small cell lung cancer (NSCLC) with advanced solid tumors were treated with JDQ443 (a KRAS-G12C inhibitor) and TNO155 (a SHP2 inhibitor). Responses were observed in both KRAS-G12C treatment-naïve and pre-treated patients, where encouraging confirmed objective response rates (ORR) were observed both groups. Dr Negrao also discusses the safety profile of the treatment, where the investigational regimen was tolerable in patients. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
